Pharmaceutical

Eyenovia (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the closing of its initial public offering of 2,730,000 shares of its common stock. As quoted in the press release: Eyenovia received $27.3 million in gross proceeds from …

Eyenovia (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced the closing of its initial public offering of 2,730,000 shares of its common stock.
As quoted in the press release:

Eyenovia received $27.3 million in gross proceeds from the offering, before underwriting discounts and commissions and other estimated offering expenses. Eyenovia has granted the underwriters a 30-day option to purchase up to 409,500 additional shares to cover over-allotments, if any. Eyenovia’s common shares are traded on the Nasdaq Capital Market under the ticker symbol “EYEN”.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20383.75+97.55
TSXV701.74+1.08
DOW32120.28+191.66
S&P 5003978.73+37.25
NASD11434.74+170.29
ASX7155.20+26.40

COMMODITIES

Commodities
Gold1847.81-6.24
Silver21.85-0.13
Copper4.24-0.01
Palladium2005.50+7.50
Platinum945.50-1.50
Oil111.09+0.76
Heating Oil3.76+0.01
Natural Gas9.16+0.19

DOWNLOAD FREE REPORTS

×